ArticleCurrent oncology (Toronto, Ont.)2015
Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.
N W D Lamond et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this paperpooled itcites it